Environmental chemicals with estrogenic activities \[xenoestrogens (XEs)\] have been implicated in harmful endocrine effects on animals and humans such as the feminization of male animal populations ([@b23-ehp0113-000431]; [@b49-ehp0113-000431]), reproductive tract malformations and endometriosis ([@b16-ehp0113-000431]; [@b26-ehp0113-000431]; [@b47-ehp0113-000431]), disorganization of the central nervous system ([@b25-ehp0113-000431]; [@b35-ehp0113-000431]), and breast and ovarian cancer ([@b4-ehp0113-000431]; [@b30-ehp0113-000431]). By acting as estrogen mimetics and binding to estrogen receptors (ERs), XEs may disrupt normal endocrine function, leading to reproductive failure and the induction of tumors in estrogen-sensitive tissues. XEs can also cause alteration of hormone levels via changes in hormone production, metabolism, or transport ([@b45-ehp0113-000431]).

There are many potential endocrine-disrupting chemicals that are prevalent in the environment, or to which humans have been otherwise exposed ([@b43-ehp0113-000431]); in this study we examined several representative compounds. Erroneously used to prevent miscarriages in the 1950s and 1960s, diethylstilbestrol (DES) acts developmentally as a potent estrogen agonist, causing adenocarcinomas, squamous neoplasia of the vagina and cervix ([@b19-ehp0113-000431]), oligospermia (vom [@b50-ehp0113-000431]), and infertility ([@b36-ehp0113-000431]). The pesticide *o*′*,p*′-dichlorodiphenylethylene (DDE) and its metabolites can disorder prostate maturation ([@b17-ehp0113-000431]). Endocrine disruptors are known to have great impact during fetal development when endogenous hormones regulate cell differentiation and growth, and thus slight alterations in hormonal activity due to endocrine disruption can lead to irreversible changes ([@b11-ehp0113-000431]). However, the abilities of XEs to disrupt adult endocrine function and perhaps to exacerbate estrogen-dependent tumor growth ([@b46-ehp0113-000431]) are also of concern. We also examined other XEs reported to have estrogen-like activities: detergents such as nonylphenol and bisphenol A (BPA), the organochlorine pesticides dieldrin and endosulfan, and the phytoestrogen coumestrol.

Estrogenic actions have been well studied with respect to genomic responses mediated by nuclear ERs. The nuclear ER-mediated gene transcription responses to XEs are very weak \[effective only at 1,000- to 10,000-fold higher concentrations than estradiol (E~2~; [@b29-ehp0113-000431]; [@b48-ehp0113-000431]; [@b56-ehp0113-000431])\], leading some to suggest that their presence in our environment is relatively harmless. However, in addition to classical genomic actions, estrogens can act through non-genomic or membrane-initiated signaling pathways via a membrane form of ER (mER). Examples of such actions are alterations in G-protein--coupled receptor responses, protein phosphorylation, lysosomal membrane destabilization, K^+^ and Ca^2+^ channel activation, and nitric oxide secretion (reviewed by [@b53-ehp0113-000431], [@b54-ehp0113-000431]). XE actions via nongenomic pathways remain largely unstudied.

Ca^2+^ responses to extracellular stimuli can lead to changes in cell motility, intra- and extracellular signaling processes, and rapid hormone secretion \[including prolactin (PRL)\] through exocytosis ([@b8-ehp0113-000431]; [@b37-ehp0113-000431]; [@b52-ehp0113-000431]). Changes in PRL secretion are associated with hormonal regulation of lactation, cell proliferation, the cellular immune response, and parental/maternal behavior ([@b13-ehp0113-000431]). We recently showed that picomolar to nanomolar concentrations of E~2~ and XEs can initiate mitogen-activated protein kinase activation and that several signaling pathways, including Ca^2+^ elevation, may participate in this kinase activation ([@b5-ehp0113-000431]; [@b6-ehp0113-000431]). We also demonstrated the ability of a physiological estrogen (E~2~) to elicit cellular Ca^2+^ influx via a membrane version of ER-α([@b7-ehp0113-000431]). Here we investigate in more detail the ability of several XEs (DES, coumestrol, *p*-nonylphenol, BPA, DDE, dieldrin, and endosulfan) to induce rapid intracellular Ca^2+^ changes leading to PRL secretion in mER-α--enriched or depleted sublines of GH3/B6 cells ([@b37-ehp0113-000431]). Mis-regulation of such cellular signaling events by XEs could lead to damaging endocrine disruptions such as tissue malformation, cancer, and reproductive system malfunctions.

Materials and Methods
=====================

We purchased phenol red-free Dulbecco modified Eagle medium (DMEM) from Mediatech (Herndon, VA); horse serum from Gibco BRL (Grand Island, NY); defined supplemented calf sera and fetal bovine sera from Hyclone (Logan, UT); endosulfan and DDE from Ultra Scientific (North Kingstown, RI); and all other XEs from Sigma (St. Louis, MO). Paraformaldehyde and glutaraldehyde were purchased from Fisher Scientific (Pittsburgh, PA). We purchased nifedipine and thapsigargin from Calbiochem (San Diego, CA) and Fura-2/AM from Molecular Probes (Eugene, OR). All other materials were purchased from Sigma.

Cell culture.
-------------

Clonal rat prolactinoma cell lines were selected for high (GH3/B6/F10) and low (GH3/B6/D9) expression of mER-α ([@b37-ehp0113-000431]). For the present experiments, cells were subsequently reselected by immunopanning for highly enriched and deficient expression of mER-α and then used between passages 2 and 12. Cells were routinely cultured in DMEM containing 12.5% horse serum, 2.5% defined supplemented calf serum, and 1.5% fetal calf serum. For individual experiments, cells were deprived of steroids for 48 hr after plating by replacing serum-containing DMEM with DMEM containing 5 μg/mL insulin-transferrin and 5 ng/mL sodium selenite, 0.1% bovine serum albumin (BSA), 20 mM sodium pyruvate, and 25 mM HEPES (DMEM/ITS). Immediately before the experiments, cells were incubated in DMEM alone for 1 hr.

Ca^2+^ measurements.
--------------------

GH3/B6 cell sublines were plated on poly-[d]{.smallcaps}-lysine--coated coverslips in wells of a six-well plate (10^5^ cells/well). After serum deprivation in DMEM/ITS and then DMEM, the cells were washed in Ringer's solution (120 mM NaCl, 1.25 mM CaCl~2~, 4.7 mM KCl, 1.2 mM MgCl~2~, 20 mM HEPES, 10 mM glucose, 0.1% BSA; pH 7.4), loaded with 2 μM Fura-2/AM diluted in Ringer's, wrapped in aluminum foil, and incubated at room temperature (RT) for 1 hr. The cells were washed twice and left to equilibrate in Ringer's for 20 min at RT before imaging. E~2~ and XEs were administered using a perfusion pump system at a rate of 2 mL/min. Although responses to E~2~ continue during a 5-min hormonal treatment, these effects are reversible, taking about 5 min to wash out ([@b7-ehp0113-000431]). Imaging was performed using a TE200-IUC Quantitative Fluorescence Live-Cell and Multidimensional Imaging System equipped with a digital monochrome cooled CCD Roper Coolsnap HQ camera (Roper Scientific, Tucson, AZ). Ca^2+^ measurements were collected using the MetaFluor program (Universal Imaging, Downingtown, PA), making sure that only single cells were used as the region of interest. Data were recorded every second. Signals were obtained in dual excitation mode (340/380 nm), and the intracellular Ca^2+^ was calculated as a ratio (*R*~340/380~) of emission data collected at 510 nm after background subtraction. Intracellular Ca^2+^ was quantified by calculating the change in fluorescence ratio (*R* -- *R*~0~) during a 5-min treatment period, normalized to the basal fluorescence value (*R*~0~) for each individual cell. These calculations for individual cells were then averaged to calculate the means and SEs for the population. Test and calibration solutions included Ca^2+^-free solution (Ringer's without CaCl~2~ and with 2 mM EGTA), Ringer's--20 mM KCl (Ringer's with NaCl decreased to 105 mM and KCl increased to 20 mM), and maximum Ca^2+^ solution (Ringer's with NaCl decreased to 112 mM and CaCl~2~ increased to 10 mM). KCl treatments were used at the end of each experiment to establish cell viability. Cells that did not respond transiently to KCl depolarization at the end of the experiment were eliminated from the composite calculations.

PRL release and radioimmunoassay.
---------------------------------

Cells (0.5--0.7 × 10^6^) were plated in poly-[d]{.smallcaps}-lysine--coated six-well plates. After serum deprivation in DMEM/ITS, this medium was removed and new DMEM/0.1% BSA with or without the appropriate reagent or vehicle control (ethanol) was added. The cells were incubated for 1, 3, 6, 10, or 15 min and centrifuged at 4°C, 350 × *g*, for 5 min. The supernatant was then collected and stored at −20°C until radioimmunoassay (RIA). Concentrations of PRL were determined using components of the rat PRL RIA kit from the National Institute of Diabetes and Digestive and Kidney Disease and the National Hormone and Pituitary Program (Baltimore, MD). Briefly, RIA buffer \[80% phosphate-buffered saline (PBS), 20% DMEM, 2% normal rabbit serum\], 100 μL cold standard (rat PRL-RP-3) or unknown sample, rPRL-s-9 antiserum (final dilution of 1:437,500 in RIA buffer), and \[^125^I\]-rat-PRL (PerkinElmer, Wellesley, MA, USA; using 15,000 counts per tube diluted in RIA buffer) were combined and incubated with shaking, overnight at 4°C. Anti-rabbit IgG (R-0881; Sigma) was added to a final dilution of 1:9, and the samples were incubated with shaking at RT for 2 hr. One milliliter of polyethylene glycol solution \[1.2 M polyethylene glycol (P-6667; Sigma), 50 mM Tris, pH 8.6\] was then added, and the samples were incubated with shaking at RT for 15 min. The samples were then centrifuged at 4,000 × *g* for 10 min at 4°C, the supernatant was decanted, and the pellet was counted in a Wizard 1470 Gamma Counter (PerkinElmer, Boston, MA). The PRL concentration was then calculated and normalized to the crystal violet values representing cell number.

Crystal violet assay.
---------------------

We used the crystal violet assay to determine cell number to which PRL concentrations were normalized. After collecting the supernatant from the PRL assay, cells were fixed by adding 1 mL fixative (2% paraformaldehyde, 0.1% glutaraldehyde, dissolved in PBS) per well. Sample plates were then rocked at RT for 30 min. The plates were then washed three times with deionized water and allowed to dry overnight. Crystal violet solution (1 mL of a 0.1% solution in water, filtered) was added to each well, and the plates were incubated with rocking at RT for 30 min. The plates were then washed and dried, and the dye was extracted with 1 mL per well of a 10% acetic acid solution (in water). After a 30 min incubation at RT, the absorbance at 590 nm was read in a model 1420 Wallac microplate reader (PerkinElmer, Boston, MA).

Statistics.
-----------

We calculated the statistical significance of differences using Sigma Stat (version 3.0; Jandel Scientific, San Rafael, CA) and one-way analysis of variance.

Results
=======

XEs increase intracellular Ca^2+^ levels.
-----------------------------------------

We previously showed that E~2~ can trigger a rapid and reversible (within 5 min) intracellular Ca^2+^ change (increase from basal level) in our mER-α--enriched (F10) rat prolactinoma cell subline, whereas the mER-α--depleted (D9) subline showed no Ca^2+^ response ([@b7-ehp0113-000431]). In the present study, E~2~ and all XEs studied initiated a change in intracellular Ca^2+^ levels (increased frequency and/or amplitude) within 30 sec of administration in mER-α--enriched F10 cells ([Figures 1](#f1-ehp0113-000431){ref-type="fig"} and [2](#f2-ehp0113-000431){ref-type="fig"}). Untreated cells during this testing period do not show a response ([@b7-ehp0113-000431]). Each compound produced a unique dose--response pattern with respect to potency, peak height, and/or frequency. All XEs elicited concentration-dependent responses; at the highest concentrations tested (10^−9^--10^−8^ M), although all XEs caused a response, generally they did so less robustly or potently when compared with E~2~. E~2~ showed a significant intracellular Ca^2+^ change at concentrations as low as 10^−12^ M, and increased with concentration. DES gave a similar response, although somewhat less robustly. Coumestrol was also effective at all tested concentrations; however, its maximal response (10^−8^ M) was half that caused by E~2~. Nonylphenol elicited concentration-dependent increases in Ca^2+^ influxes with similar characteristics to E~2~, but with the most robust response at 10^−8^ M being slightly lower than that for E~2~. BPA displayed a maximal response at 10^−9^ M that declined at a higher concentration. DDE produced the smallest Ca^2+^ elevations. Dieldrin elicited a Ca^2+^ change at all concentrations. Endosulfan caused no intracellular Ca^2+^ changes at the lowest concentrations, yet 10^−9^ M and 10^−8^ M produced quite robust influx. When we examined individual cells, we found that they were heterogeneous in their responsiveness to XEs, as we have observed previously in responses to E~2~ ([@b52-ehp0113-000431]). Overall, 82% of the cells tested responded to treatment with E~2~ or XEs, but some cells did not respond at all. We did not average nonresponders into the composite measurements ([Figure 2](#f2-ehp0113-000431){ref-type="fig"}), and the error measurements shown represent cells with differing response capabilities. No Ca^2+^ changes occurred upon the administration of XEs of any concentration in the mER-α--deficient D9 cells ([Figure 3](#f3-ehp0113-000431){ref-type="fig"}); for these studies we tested only a single representative compound from each category (E~2~, phytoestrogen, detergent, and organochlorine pesticide).

Intracellular Ca^2+^ stores are not responsible for E~2~-induced Ca^2+^ level changes.
--------------------------------------------------------------------------------------

To determine which sources of Ca^2+^ (intracellular, extracellular, or both) were involved in the XE-induced response, we administered thapsigargin, a cell-permeable inhibitor that releases Ca^2+^ from intracellular stores by specifically and irreversibly inhibiting endoplasmic reticular Ca^2+^ ATPase ([Figure 4](#f4-ehp0113-000431){ref-type="fig"}). We first completely emptied the intracellular stores of Ca^2+^ with the application of 1 μM thapsigargin; this is evident from the rise in intracellular Ca^2+^ levels that occurred immediately after thapsigargin application. Then, after thapsigargin treatment, E~2~ and each XE could still trigger an intracellular Ca^2+^ rise, suggesting that the intracellular induced Ca^2+^ increase comes from the extracellular pool.

Intracellular Ca^2+^ changes are due to an influx of extracellular Ca^2+^.
--------------------------------------------------------------------------

To confirm that the Ca^2+^ increase was drawn from an extra-cellular source, we tested the effect of the presence or absence of Ca^2+^ in the solution surrounding the cells. We first triggered an intracellular Ca^2+^ change with the administration of E~2~ or XEs at 10^−8^ M in normal Ringer's. We then eliminated Ca^2+^ from the extracellular solution by administering Ca^2+^-free Ringer's into the perfusion system. The cells were then treated with either 10^−8^ M E~2~ or XE diluted in Ca^2+^-free Ringer's. The effect on the response to E~2~ is shown in [Figure 5A](#f5-ehp0113-000431){ref-type="fig"}, where intracellular Ca^2+^ level increases were abolished, confirming that extracellular Ca^2+^ was the source for the intracellular Ca^2+^ elevations. These experiments were repeated for DES, coumestrol, nonylphenol, and endosulfan, with similar results ([Figure 5B](#f5-ehp0113-000431){ref-type="fig"}, averaged responses). To determine continued cell viability after treatment with Ca^2+^-free Ringer's and estrogenic compounds, we washed out the Ca^2+^-free Ringer's with normal Ringer's followed by Ringer's containing 20 mM KCl (shown only for E~2~ in [Figure 5A](#f5-ehp0113-000431){ref-type="fig"}). The cells always responded to both the normal Ringer's (by returning of the Ca^2+^ influx pattern to the normal basal level) and the Ringer's--20 mM KCl (by displaying a large and transient Ca^2+^ influx due to cell depolarization), thus demonstrating cell viability.

XE-induced Ca^2+^ influx is mediated by L-type Ca^2+^ channels.
---------------------------------------------------------------

We have recently shown that E~2~ causes an intracellular Ca^2+^ change via the L-type Ca^2+^ channel ([@b7-ehp0113-000431]). XEs mimic the response caused by E~2~, implying that they may also act via the L-type Ca^2+^ channel. To test this hypothesis, we administered nifedipine, an L-type Ca^2+^ channel blocker that inhibits Ca^2+^ influx into the cell from extracellular sources. We monitored single cells ([Figure 6](#f6-ehp0113-000431){ref-type="fig"}) and then averaged these responses from multiple cells ([Figure 7](#f7-ehp0113-000431){ref-type="fig"}) to quantitate the responses. We first triggered a Ca^2+^ response by stimulating cells with 10^−8^ M E~2~ or XEs representative of different classes (DES, coumestrol, BPA, DDE, and endosulfan). After washout of the estrogens, the addition of 10 μM nifedipine caused cessation of Ca^2+^ influx. Subsequent addition of 10^−8^ M E~2~ or XE, in the presence of nifedipine, could not elicit a Ca^2+^ influx.

XEs stimulate the rapid secretion of PRL.
-----------------------------------------

At 10^−8^ M E~2~ or XE, PRL was secreted rapidly (by 1 min), a response largely complete by 1--3 min ([Figure 8](#f8-ehp0113-000431){ref-type="fig"}) for most of the compounds (E~2~, DES, coumestrol, nonylphenol, and BPA). However, the organochlorine pesticides produced either delayed or no PRL secretion; DDE did not cause PRL secretion at any time point, and dieldrin and endosulfan stimulated PRL secretion incrementally over time with maximal secretion at 15 min, which was significantly different from their secretion level at 1 min.

XEs stimulate the rapid secretion of PRL in a dose-dependent manner.
--------------------------------------------------------------------

The E~2~ or XE concentration dependence of PRL secretion at 3 min shows differences among compounds ([Figure 9](#f9-ehp0113-000431){ref-type="fig"}). The dose--response pattern for DES resembles that for E~2~, although DES is less potent at the lower concentrations. The E~2~ and DES dose--response curves were interrupted by a single lower/inactive nanomolar dose that sits between two active doses of 10^−10^ M and 10^−8^ M. Coumestrol triggered PRL release only at the highest concentration (10^−8^ M). Nonylphenol and BPA, both detergents, show a bimodal response curve with a wide gap (interruption) at the middle concentrations; PRL secretion was only elicited at the highest and lowest concentrations. The pesticides DDE and endosulfan show similar response curves, with maximal secretion at 10^−10^ M. Dieldrin induced PRL secretion at all concentrations from 10^−12^ M to 10^−8^ M, but with no apparent dose-dependent changes across these concentrations.

PRL secretion is blocked by nifedipine.
---------------------------------------

To test whether PRL secretion occurs via the L-type Ca^2+^ channel mechanism, we administered nifedipine to block the influx of Ca^2+^ ([Figure 10](#f10-ehp0113-000431){ref-type="fig"}). E~2~ and a representative set of XEs (DES, coumestrol, and endosulfan) were tested at a 10^−8^ M concentration with and without nifedipine. Nifedipine, which blocked the entry of Ca^2+^ from the extracellular solution, also abolished the E~2~- and XE-induced PRL secretion at 3 min.

Discussion
==========

There has been much debate about the mechanisms by which XEs act. The concentrations at which XEs are believed to be mechanistically active have largely been determined by assaying for the transcriptional activity of these compounds via the well-established nuclear pathway of action for steroids. We hypothesized that XEs, like steroid hormones, can elicit both delayed (genomic) and rapid (nongenomic or membrane-initiated) responses ([@b5-ehp0113-000431]; [@b6-ehp0113-000431]; [@b54-ehp0113-000431]). We established a cell model with which to screen the rapid non-genomic activities of estrogenic compounds using cells naturally expressing high levels of a membrane form of ER-αthought to mediate these nongenomic actions. We previously demonstrated that these cells can respond rapidly to E~2~ by extracellular signal-regulated kinase (ERK) phosphorylation ([@b5-ehp0113-000431]; [@b6-ehp0113-000431]) and PRL release ([@b33-ehp0113-000431]; [@b37-ehp0113-000431]). We also recently determined that E~2~ induces a rapid Ca^2+^ influx (within 30 sec) via the L-type Ca^2+^ channel in these cells, which is necessary for rapidly induced PRL secretion ([@b7-ehp0113-000431]). However, the ability of XEs to induce mechanistic pathways related to secretion of hormones associated with endocrine-disruptive mechanisms has largely not been determined. In the present studies, we demonstrated the ability of very low (picomolar to nanomolar) concentrations of several XEs to induce a rapid Ca^2+^ influx resulting in PRL secretion.

Because we found that some XEs induced rapid mitogen-activated protein kinase (MAPK) activation via the same membrane-initiated signaling pathway used by E~2~ in pituitary tumor cells ([@b6-ehp0113-000431]), we hypothesized that XEs could mimic E~2~ in other rapid signal-generating mechanisms, including effects on intracellular Ca^2+^ levels. Our present studies thus show that, like E~2~ ([@b7-ehp0113-000431]), XEs potently induce intracellular Ca^2+^ increases in our mER-α--enriched rat prolactinoma cell line GH3/B6/F10, whereas mER-α--deficient cells cannot respond. Both physiological estrogen (E~2~) and XEs stimulate a rapid Ca^2+^ influx (within 30 sec) from the extracellular media (because elimination of extracellular Ca^2+^ abolished intracellular Ca^2+^ changes) that is independent of the release of endoplasmic reticulum Ca^2+^ stores (i.e., is thapsigargin insensitive). Blocking the L-type Ca^2+^ channels with nifedipine also abrogated XE-induced Ca^2+^ influx. Therefore, the XEs used in our study were able to cause E~2~-like changes in Ca^2+^ levels via similar mechanisms.

Increases in Ca^2+^ levels often lead to the release of many different kinds of stored hormones and other proteins from secretory vesicles ([@b22-ehp0113-000431]). GH3/B6 cells manufacture and spontaneously secrete PRL ([@b58-ehp0113-000431]); however, in addition to constitutive PRL secretion, a variety of external stimuli such as drugs or hormones can enhance the release of stored PRL from vesicles \[e.g., E~2~-induced PRL release ([@b37-ehp0113-000431])\]. These data demonstrate that environmental contaminants such as XEs of different classes (plastics manufacturing and detergent byproducts, pesticides, phytoestrogens, and synthetic estrogens) can mimic endogenous estrogens such as E~2~, causing rapid PRL secretion by raising cellular Ca^2+^ levels.

PRL is conventionally viewed as a pituitary hormone that stimulates and maintains the secretion of milk. However, PRL is also synthesized and secreted by a broad range of cells, including those of the immune system ([@b12-ehp0113-000431]; [@b38-ehp0113-000431]), breast cancers ([@b10-ehp0113-000431]), and the lining of the pregnant uterus ([@b14-ehp0113-000431]; [@b57-ehp0113-000431]). Physiological stimuli such as increased levels of ovarian steroids (primarily estrogens) can increase PRL secretion, leading to delay in puberty ([@b1-ehp0113-000431]), interference with ovulation ([@b2-ehp0113-000431]; [@b31-ehp0113-000431]), decreases in libido and fertility ([@b18-ehp0113-000431]; [@b20-ehp0113-000431]; [@b44-ehp0113-000431]), and cell proliferation ([@b24-ehp0113-000431]; [@b41-ehp0113-000431]). Behavioral effects of PRL are also known ([@b3-ehp0113-000431]; [@b28-ehp0113-000431]). Therefore, overstimulation, inappropriate stimulation (for developmental stage or reproductive cycle stage), or inhibition of PRL secretion can lead to a variety of disruptions of normal reproductive function, and our data demonstrate that XEs at low concentrations could cause such altered PRL secretion.

Each XE that we studied produced PRL release during the first 15 min of application, but most elicited a significant response by 1 min. Dose--response curves revealed intermediate inactive doses, as we ([@b6-ehp0113-000431]; [@b55-ehp0113-000431]) and others ([@b39-ehp0113-000431]) have previously observed, although we still do not have a substantiated explanation for such response gaps. Receptors that activate such responses via the membrane may be sequestered on different cellular surfaces or in different membrane compartments such as rafts and caveolae ([@b40-ehp0113-000431]; [@b42-ehp0113-000431]), which could produce different receptor subpopulations with different dose--response characteristics. It is interesting to note that the Ca^2+^ response did not display such a bimodal dose--response pattern, so additional signaling mechanisms besides Ca^2+^ must be responsible for these differential dose patterns, as we have suggested previously in studies that noted differences between E~2~- and KCl- induced Ca^2+^ levels and resulting PRL secretion ([@b7-ehp0113-000431]).

Increased Ca^2+^ levels can trigger the release of PRL and other hormones from secretory vesicles, but it can also initiate signaling cascades leading to a variety of kinase activations (e.g., adenylyl cyclase production of cAMP leading to activation of protein kinase A, phospholipase C activation resulting in activation of protein kinase C, calmodulin activation of pathways leading to MAP kinase phosphorylation, etc.), resulting in changes in the phosphorylation status of a variety of cellular proteins leading to rapid functional consequences. These signaling cascades are now known to be rapidly stimulated by steroid hormones (reviewed by [@b53-ehp0113-000431], [@b54-ehp0113-000431]). For example, E~2~ induces a rapid increase in cAMP that parallels the changes in Ca^2+^ uptake in duodenal cells ([@b39-ehp0113-000431]), and E~2~ has been shown to increase cytosolic Ca^2+^ levels as well as induce MAPK activation in hemocytes ([@b9-ehp0113-000431]). Steroid-induced Ca^2+^ influxes have also been reported in ovarian, prostate, cardiac and vascular smooth muscle, and bone cells (reviewed by [@b53-ehp0113-000431]). The list of cell types and stages in which steroids can induce Ca^2+^ changes is rapidly growing and becoming a hallmark of non-genomic steroid action; examples now exist for most classes of steroids (reviewed by [@b51-ehp0113-000431]; [@b53-ehp0113-000431], [@b54-ehp0113-000431]).

Some researchers have speculated that the ER that mediates XE effects is a unique receptor ([@b15-ehp0113-000431]; [@b32-ehp0113-000431]). However, our studies demonstrate that sub-clones of GH3/B6 cells that substantially lack the membrane version of ER-α\[D9 subline ([@b37-ehp0113-000431])\] cannot respond to E~2~ or XEs via Ca^2+^ fluxes, PRL release (these studies), or ERK activation ([@b5-ehp0113-000431]; [@b6-ehp0113-000431]). This is in keeping with our previous investigations that indicated the involvement of an ER-αprotein in these rapid responses in several ways. E~2~-induced PRL release was blocked in cells inhibited with the ER antagonist ICI 182,870 ([@b7-ehp0113-000431]) or treated with specific ER-αantibodies ([@b33-ehp0113-000431]). The mER expression in these same cells was abolished by ER-αby antisense strategies ([@b34-ehp0113-000431]). Of course, it is possible that other components besides mER-αare necessary, but the lack of ER-αin the membrane prevents signaling responses to these compounds.

XEs pose a potential environmental threat to human health because experimental animal exposures have demonstrated endocrine developmental anomalies at levels similar to those sometimes seen in environmental contamination. However, most previous studies have emphasized the genomic mechanisms of XE action, which require very high concentrations. Our research has instead focused on the rapid, nongenomic or membrane-initiated effects of these environmental contaminants. Via these alternate signaling pathways, estrogen mimetics such as XEs could interfere with endogenous estrogen actions via multiple mechanisms. By eliciting, enhancing, or inhibiting estrogenic signaling, they may interfere with physiological estrogenic signals, affecting many downstream functions. Each XE however, shows unique temporal and dose-responsive patterns, possibly due to the differential involvement of companion signaling pathways. Although we have linked XEs to rapid cellular events that trigger intracellular Ca^2+^ influxes and PRL secretion, further study is needed to fully understand all of these differentially activated signaling cascades and their relationships to the myriad outcomes of XE exposure.

![Intracellular Ca^2+^ changes induced by (*A*) E~2~, (*B*) DES, (*C*) coumestrol, (*D*) *p*-nonylphenol, (*E*) BPA, (*F*) DDE, (*G*) dieldrin, and (*H*) endosulfan. Each Ca^2+^ profile (340/380 nm trace) is a single representative cell. See "Materials and Methods" for details of experiments.](ehp0113-000431f1){#f1-ehp0113-000431}

![Intracellular Ca^2+^ changes induced by (*A*) E~2~ (*n* = 24 cells/3 experiments), (*B*) DES (*n* = 19 cells/3 experiments), (*C*) coumestrol (*n* = 12 cells /4 experiments), (*D*) *p*-nonylphenol (*n* = 12 cells/4 experiments), (*E*) BPA (*n* = 15 cells /4 experiments), (*F*) DDE (*n* = 7 cells /3 experiments), (*G*) dieldrin (*n* = 20 cells/3 experiments), and (*H*) endosulfan(*n* = 19 cells /4 experiments). Bars display the change in fluorescence ratio divided by the basal fluorescence \[(*R* -- *R*~0~)/*R*~0~\], averaged from multiple imaged GH3/B6/F10 cells over several experiments (mean ± SE).\
\*Statistically significant from basal level (*p* \< 0.05).](ehp0113-000431f2){#f2-ehp0113-000431}

![Lack of Ca^2+^ responses in mER-α--deficient D9 cells treated with (*A*) E~2~ (*n* = 28 cells/3 experiments), (*B*) coumestrol (*n* = 17 cells/3 experiments), (*C*) *p*-nonylphenol (*n* = 6 cells /3 experiments), and (*D*) endosul-fan (*n* = 7 cells/3 experiments). Bars display the change in fluorescence ratio divided by the basal fluorescence \[(*R* -- *R*~0~)/*R*~0~\], averaged for multiple imaged cells over several experiments (mean ± SE). No values were significantly different from the basal.](ehp0113-000431f3){#f3-ehp0113-000431}

![Effect of thapsigargin (Tg) on XE-induced intracellular Ca^2+^ changes. Intracellular Ca^2+^ stores were emptied by the addition of 1 μM Tg, and cells were then treated with 10^−8^ M E~2~ or XE. (*A* and *B*; *n* = 12 cells/3 experiments), DES (*C* and *D*; *n* = 12 cells/3 experiments), coumestrol (Coum; *E* and *F*; *n* = 6 cells/ 3 experiments), or *p*-nonylphenol (NP; *G* and *H*; *n* = 8 cells/3 experiments). Each trace (*A,C,E,G)* represents a single representative cell; bar graphs (*B,D,F,H*) represent multiple imaged cells over several experiments (mean ± SE).\
\*Statistically different from basal level (*p* \< 0.05).](ehp0113-000431f4){#f4-ehp0113-000431}

![Effect of Ca^2+^-free extracellular solution on XE-induced Ca^2+^ fluxes. (*A*) Representative trace for E~2~ with the following sequential treatments: 1) 10 nM E~2~ in normal Ringer's, 2) Ca^2+^-free Ringer's added, 3) 10 nM E~2~ in the presence of Ca^2+^-free Ringer's, 4) wash with normal Ringer's, and 5) Ringer's--20 mM KCl. (*B*) Represents the same treatment sequence shown in (*A*) for DES (*n* = 7 cells/3 experiments); coumestrol (Coum; *n* = 8 cells/3 experiments); *p*-nonylphenol (NP; *n* = 5 cells/3 experiments); and endosulfan (End; *n* = 6 cells/3 experiments). Values shown are mean ± SE for \[(*R* -- *R*~0~)/*R*~0~\] for multiple imaged cells over several experiments.\
\*Statistically different from the basal level (*p* \< 0.05). \*\*Statistically different from the E~2~- or XE-treated value (*p* \< 0.05).](ehp0113-000431f5){#f5-ehp0113-000431}

![Effect of nifedipine (Nifed) on intracellular Ca^2+^ changes induced by (*A*) E~2~, (*B*) DES, (*C*) coumestrol (Coum), (*D*) BPA, (*E*) endosulfan (End), or (*F*) DDE. GH3/B6/F10 cells were treated with E~2~ or the indicated XE at 10^−8^ M, and 10 μM Nifed was then added, followed by a second addition of 10^−8^ M E~2~ or XE in the presence of 10 μM Nifed. Each trace is a single representative cell.](ehp0113-000431f6){#f6-ehp0113-000431}

![Cell effects of nifedipine (Nifed) on XE-induced intracellular Ca^2+^ increases (mean ± SE) induced by (*A*) E~2~ (*n* = 8 cells/3 experiments), (*B*) DES (*n* = 8 cells/ 3 experiments), (*C*) coumestrol (Coum; *n* = 9 cells/3 experiments), (*D*) BPA (*n* = 16 cells/4 experiments), (*E*) DDE (*n* = 9 cells/3 experiments), and (*F*) endosulfan (End; *n* = 9 cells/3 experiments). GH3/B6/F10 cells were treated with E~2~ or the indicated XE at 10^−8^ M, and 10 μM Nifed was then added, followed by a second addition of E~2~ or XE (10^−8^ M) in the presence of 10 μM Nifed. Bars indicate the change in fluorescence ratio divided by the basal fluorescence \[(*R* -- *R*~0~)/*R*~0~\], averaged for multiple imaged cells over several experiments.\
\*Statistically different from the basal level (*p* \< 0.05). \*\*Statistically different from the E~2~- or XE-stimulated value (*p* \< 0.05).](ehp0113-000431f7){#f7-ehp0113-000431}

![Time dependence (mean ± SE) of XE-induced PRL release in GH3/B6/F10 cells. (*A*) E~2~ (*n* = 16 samples/4 experiments), (*B*) DES (*n* = 20 samples/5 experiments), (*C*) coumestrol (*n* = 24 samples/6 experiments), (*D*) *p*-nonylphenol (*n* = 20 samples/4 experiments), (*E*) BPA (*n* = 20 samples/4 experiments), (*F*) DDE (*n* = 20 samples/ 4 experiments), (*G*) dieldrin (*n* = 20 samples/4 experiments), or (*H*) endosulfan (*n* = 20 samples/4 experiments). PRL/CV represents the percentage of the basal PRL secretion at each individual time point, normalized to the cell number \[crystal violet (CV) signal\]. Dashed lines indicate the error range surrounding the basal level.\
\*Statistically different from the basal level (*p* \< 0.05). \*\*Statistically different from the 1-min treated value (*p* \< 0.05).](ehp0113-000431f8){#f8-ehp0113-000431}

![XE-induced concentration-dependent PRL release (mean ± SE) in GH3/B6/F10 cells treated for 3 min with (*A*) E~2~ (*n* = 28 samples/7 experiments), (*B*) DES (*n* = 12 samples/3 experiments), (*C*) coumestrol (*n* = 20 samples/5 experiments), (*D*) *p*-nonylphenol (*n* = 12 samples/3 experiments), (*E*) BPA (*n* = 16 samples/ 4 experiments), (*F*) DDE (*n* = 16 samples/4 experiments), (*G*) dieldrin (*n* = 20 samples/5 experiments), (*H*) endosulfan (*n* = 24 samples/6 experiments). PRL/CV represents the percentage of the basal PRL secretion at each individual time point, normalized to the cell number \[crystal violet (CV) signal\]. Dashed lines indicate the error range around the basal level.\
\*Statistically different from the basal level (*p* \< 0.05).](ehp0113-000431f9){#f9-ehp0113-000431}

![Inhibition of XE-induced PRL secretion (mean ± SE) by nifedipine (Nifed) in GH3/B6/F10 cells treated with E~2~ or XE at 10^−8^ M with or without 10 μM Nifed. E~2~ (*n* = 28 samples/7 experiments); E~2~/Nifed (*n* = 32 samples/8 experiments); DES (*n* = 24 samples/ 6 experiments); DES/Nifed (*n* = 28 samples/7 experiments); coumestrol (Coum; *n* = 24 samples/6 experiments); Coum/Nifed (*n* = 28 samples/7 experiments); endosulfan (End; *n* = 24 samples/6 experiments); End/Nifed; *n* = 24 samples/6 experiments). PRL/CV represents the percentage of the basal PRL secretion at each individual time point, normalized to the cell number \[crystal violet (CV) signal\]. Dashed lines indicate the error range around the basal level.\
\*Statistically different from the basal level (*p* \< 0.05). \*\*Statistically different from the E~2~- or XE-treated value (*p* \< 0.05).](ehp0113-000431f10){#f10-ehp0113-000431}
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